E-mail address: troussard-x@chu-caen.fr Laboratoire d’Hématologie, CHU Caen, Caen, France.
EM, EC, VS, and DN: performed and reviewed the biological vHCL diagnosis.Please check your email for instructions on resetting your password. On clinical examination, there was a large splenomegaly, edema of the lower limbs, and dyspnoea on exertion. See the complete profile on LinkedIn and discover Françoise’s connections and jobs at similar companies.
Name must be less than 100 characters
2014 Mar 26;34(13):4466-80. doi: 10.1523/JNEUROSCI.4314-13.2014.J Neuroinflammation. These cases further underscore that the therapeutic armamentarium for vCHL could be diverse, ranging from ibrutinib to splenectomy.MW: collected information on patients and drafted the manuscript. The hematologic parameters indicating a need for treatment include at least one of the following: hemoglobin <11 g/dL; platelet count <100 G/L; absolute neutrophil count <1 G/L.
Data from worldwide cancer registries and studies tend to demonstrate an increased incidence of secondary cancers; This is especially true for hematological malignancies, with cumulative incidence varying from 5% to 32%, probably depending on the time of follow‐up.New opportunities have emerged in recent years, leading to a better understanding of HCL and a better management of HCL patients. 4 UMS 3408 Support Cyceron, CNR, Universite de Caen Normandie, CHU de Caen, GIP CYCERON, Caen, France. First‐line option relies on the association of cladribine with rituximab, combinedNote, SDRPL should be distinguished from HCL‐V by performing splenectomy.
Cytological aspects of hairy cell leukemia (HCL) (A) and HCL variant (HCL‐V) (B)Therapeutic algorithm for treatment of patients with hairy cell leukemia (HCL)Therapeutic algorithm for treatment of patients with hairy cell leukemia variant (HCL‐V) and splenic diffuse red pulp lymphomas (SDRPL) ... (centre de prélèvement du CHU).
There was bone marrow infiltration (15%) by lymphoid cells expressing B‐cell markers CD19, FMC7, CD20, and CD79b, as well as a monotypic kappa light chain and the CD11c and CD103 without expressing CD25 and CD123 (Figure The presence of hairy cells in a blood smear could suggest a diagnosis of cHCL, vHCL, SMZL, or SDRPL.In both patients, we retained the diagnosis of vHCL.
Proposal for a scoring system to distinguish HCL from B‐cell disorders with hairy or villous lymphocytesConsensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaWHO Classification of Tumours of Haematopietic and Lymphoid TissuesDifferential expression of CD43, CD81, and CD200 in classic versus variant hairy cell leukemiaRelevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B‐cell lymphoma (SRPL)Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCLInitial genome sequencing and analysis of multiple myelomaAlternative BRAF mutations in BRAF V600E‐negative hairy cell leukaemiasHigh prevalence of MAP2K1 mutations in variant and IGHV4‐34–expressing hairy‐cell leukemiasNew generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genesMEK1 mutations confer resistance to MEK and B‐RAF inhibitionTargeting Mutant BRAF in Relapsed or Refractory Hairy‐Cell LeukemiaBRAF V600E mutation in hairy cell leukemia: from bench to bedsideGenome‐wide promoter methylation of hairy cell leukemiaEvidence of canonical somatic hypermutation in hairy cell leukemiaHairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single‐agent cladribine and with more aggressive behaviorInsight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patternsBoth variant and IGHV4‐34–expressing hairy cell leukemia lack the BRAF V600E mutationHematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemiaLangerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergenceHematopoietic origin of langerhans cell histiocytosis and Erdheim‐Chester disease in adultsRecurrent CDKN1B (p27) mutations in hairy cell leukemiaGenomic analysis of hairy cell leukemia identifies novel recurrent genetic alterationsp53 gene deletion and trisomy 12 in hairy cell leukemia and its variantThe Krüppel‐like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphomaExome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B‐cell lymphomaKLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotypeSplenic diffuse red pulp small B‐cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutationsSplenic diffuse red pulp small‐B cell lymphoma: toward the emergence of a new lymphoma entitySplenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B‐cell malignanciesCD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapyVH4‐34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapyResponse to the therapy in hairy cell leukemia: systematic review and meta‐analysisLong‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemiaCharacteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysisLong‐term follow‐up after purine analogue therapy in hairy cell leukaemiaLong‐term results for pentostatin and cladribine treatment of hairy cell leukemiaLong‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialRandomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemiaRituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrenceObinutuzumab in multidrug‐resistant hairy cell leukemiaRecommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow‐up of hairy cell leukaemiaMRD‐negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumabBendamustine and Rituximab in relapsed and refractory hairy cell leukemiaBRAF inhibition in hairy cell leukemia with low‐dose vemurafenibProgression of RAS‐mutant leukemia during RAF inhibitor treatmentBRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemiaMoxetumomab pasudotox in relapsed/refractory hairy cell leukemiaThree‐Year follow‐up of treatment‐naive and previously treated patients with CLL and SLL receiving single‐agent ibrutinibCurrent therapy and new directions in the treatment of hairy cell leukemia: a review current therapy and new directions in hairy cell leukemia current therapy and new directions in hairy cell leukemiaHairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow‐upBRAF V600E mutation‐specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemiaPeripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high‐risk patientsMinimal residual hairy cell leukemia eradication with Moxetumomab Pasudotox: phase I results and long‐term follow‐upCladribine with immediate Rituximab for the treatment of patients with variant hairy cell leukemiaIbrutinib for relapsed refractory hairy cell leukemia variantBurkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomicsSecond malignancies in patients with hairy cell leukemia in British Columbia: a 20‐year experienceSecond malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemiasRisk of second cancer in patients with hairy cell leukemia: long‐term follow‐upSecond cancer incidence and cause‐specific mortality among 3104 patients with hairy cell leukemia: a population‐based StudySecond primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemiaOutcomes and second neoplasms in hairy cell leukemia: a retrospective cohortTypes of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patientsLong‐term follow‐up of patients with hairy cell leukemia after cladribine treatmentWhole‐genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphomaConcurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features, Bone lesions in hairy cell leukemia: Diagnosis and treatment,